PharmiWeb

C2N Diagnostics Releases the PrecivityAD2™ Blood Test for Clinical Care, a Robust Assay with High Concordance to Amyloid PET and CSF

PrecivityAD2 Aims to Set a New Performance Standard for Blood Biomarkers in Alzheimer’s Disease Diagnosis With Combined Measures of Amyloid Beta (Aβ42/40) and Tau Protein (p-tau217/np-tau217) Ratios ...
Business Wire

C2N Diagnostics Expands the PrecivityAD2™ Alzheimer’s Disease Blood Test Intended Use to Patients 50 Years and Older

ST. LOUIS--(BUSINESS WIRE)--Clinicians worried about early-onset Alzheimer’s disease in patients with cognitive concerns between the ages of 50 and 55 years can now prescribe the PrecivityAD2™ blood ...
Business Wire

New Research Reinforces C2N’s PrecivityAD2™ Blood Test as a Highly Accurate Tool to Detect Brain Amyloid Pathology in Symptomatic Patients

ST. LOUIS--(BUSINESS WIRE)--C2N Diagnostics, LLC (“C2N”), a specialty diagnostics company with a vision to bring Clarity Through Innovation®, is highlighting a peer-reviewed study that independently ...
BioWorld

C2N, Quanterix blood tests diagnose 90% of early-stage Alzheimer's

C2N Diagnostics LLC’s two-factor blood test, Precivity AD2, showed 90% accuracy in diagnosing Alzheimer’s disease in a study presented at the Alzheimer’s Association International Conference in ...
MarketWatch

JAMA Publishes Landmark Clinical Study Showing C2N Diagnostics' PrecivityAD2(TM) Blood Test Markedly Improves Accuracy of AD Diagnosis in Both Primary Care and Specialized ...

The Journal of the American Medical Association (JAMA) has published a large clinical study examining the ability of C2N Diagnostics, LLC's (C2N) PrecivityAD2(TM) blood test to improve the diagnostic ...
Financial Post

First Canadian Clinic to Offer C2N's PrecivityAD2™ Blood Test to Help Healthcare Providers Diagnose Alzheimer's Disease, Joining Global Community in Embracing Breakthrough ...

The prevalence of Alzheimer’s disease in Canada is estimated at over 600,000 people, with even higher numbers of people at the mild cognitive impairment stage of the disease. Researchers have ...
Pharmabiz

C2N Diagnostics releases PrecivityAD2 blood test for clinical care, a robust assay with high concordance to amyloid PET & CSF

C2N Diagnostics, a leader in advanced brain health diagnostics, announced the release of the PrecivityAD2 blood test, a clinical care assay that meets the standard of care with currently available PET ...